New Perspectives of Central Nervous System Injury and Neuroprotection - 1st Edition - ISBN: 9780123869869, 9780123870162

New Perspectives of Central Nervous System Injury and Neuroprotection, Volume 102

1st Edition

Serial Volume Editors: Hari Shanker Sharma
eBook ISBN: 9780123870162
Hardcover ISBN: 9780123869869
Imprint: Academic Press
Published Date: 10th July 2012
Page Count: 424
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Series Page
  • Contributors
  • Preface
  • Acknowledgments
  • Chapter 1 The Function and Mechanisms of Nurr1 Action in Midbrain Dopaminergic Neurons, from Development and Maintenance to Survival
    • I Introduction
    • II The Midbrain Dopamine System: Neurochemistry
    • III The Midbrain Dopamine System: Development
    • IV Dopaminergic Neurons and Parkinson’s Disease
    • V Nurr1, A Protein Whose Function Is Important in the Life Cycle of VM DANs
    • VI The Mechanisms of Nurr1 as a Nuclear Receptor
    • VII Most Recent Development in Application of Nurr1 in Dopaminergic Differentiation and Implications in Future Treatment for PD
  • Chapter 2 Monoclonal Antibodies as Novel Neurotherapeutic Agents in CNS Injury and Repair
    • I Introduction
    • II Historical Perspectives on the Use of Antibodies as Therapy
    • III Therapeutic Basis of Antibodies
    • IV Antibodies Versus Receptor Antagonist Drugs
    • V Antibodies Neutralize Effects of Endogenous Antigens
    • VI Our Investigations on Monoclonal Antibodies to Induce Neuroprotection in CNS Injuries
    • VII Neuroprotective Effects of Serotonin Antibodies in CNS Injuries
    • VIII Neuroprotection by Dynorphin A Antibodies in CNS Injuries
    • IX Antibodies to nNOS Is Neuroprotective in CNS Injuries
    • X TNF-α Antibodies Are Neuroprotective in CNS Injuries
    • XI Combination of nNOS and TNF-α Antibodies Enhances Neuroprotection in SCI
    • XII Conclusion and Future Perspectives
  • Chapter 3 The Blood–Brain Barrier in Alzheimer’s Disease
    • I Introduction
    • II Pathology of AD
    • III A Receptor-Mediated Transport of apoJ and ABP at the BBB and BCSF-B
    • IV Human Receptors for ABP1-40
    • V Clearance of AB1-40 P from Brain LDL Receptor at the BBB
    • VI Clearance of ABP1-40 in Monkey Model
    • VII Point Mutation of Codon 22 Reduces Clearance of ABP1-40 from the CSF and Prevents Transport from CNS to Blood
    • VIII Circulating ABP Crosses the BBB in Aged Monkeys
    • IX Cerebrovascular Pathology in AD
    • X Existing Theories Regarding Origin of ABP
    • XI Conclusion
  • Chapter 4 Neurovascular Aspects of Amyotrophic Lateral Sclerosis
    • I Introduction
    • II BBB/BSCB Impairment in ALS
    • III Future Perspectives
    • IV Conclusion
  • Chapter 5 Quercetin in Hypoxia-Induced Oxidative Stress: Novel Target for Neuroprotection
    • I Introduction
    • II Hypoxia and Free Radical Generation
    • III Brain: Target to Free Radical Damage
    • IV Antioxidant Defense System
    • V Antioxidant Defense System and Hypoxia
    • VI Pathophysiological Changes in Brain in Response to Hypoxia
    • VII Antioxidant Therapy
    • VIII Our Investigation on Neuroprotection Elicited by Quercetin
    • X General Conclusion and Future Perspective
  • Chapter 6 Environmental Conditions Modulate Neurotoxic Effects of Psychomotor Stimulant Drugs of Abuse
    • I Introduction
    • II Brain Temperature Responses to METH and MDMA are Modulated by Activity State and Environmental Conditions
    • III Adverse Environmental Conditions Enhance Histochemical and Morphological Perturbations Induced by METH: Role of Brain Temperature
    • IV Temperature Modulation of BBB Permeability
    • V Conclusions and Perspectives
  • Chapter 7 Central Nervous Tissue Damage after Hypoxia and Reperfusion in Conjunction with Cardiac Arrest and Cardiopulmonary Resuscitation
    • I Introduction
  • Chapter 8 Interactions Between Opioids and Anabolic Androgenic Steroids: Implications for the Development of Addictive Behavior
    • I Introduction
    • II AAS May Lead to Opioid Dependence
    • III Interactions Between AAS and the Endogenous Opioids
    • IV AAS Dependence Involve Opioid Mechanisms
    • V Conclusions
  • Chapter 9 Neurotrophic Factors and Neurodegenerative Diseases
    • I Introduction
    • II NTFs and Neurodegenerative Diseases
    • III NTF Delivery Approaches: Evolution in Therapies
    • IV Conclusion
  • Chapter 10 Neuroprotective Effects of Cerebrolysin, A Combination of Different Active Fragments of Neurotrophic Factors And Peptides on the Whole Body Hyperthermia-Induced Neurotoxicity
    • I Introduction
    • II Blood–Brain Barrier—A Gateway to Brain Diseases
    • III Factors Affecting Hyperthermia-Induced Brain Damage
    • IV Cerebrolysin, a Novel Therapeutic Agent in Hyperthermia-Induced Neurotoxicity
    • V Functional Significance of These Findings
    • VI Conclusions
    • VII Future Perspectives
  • Chapter 11 Alzheimer’s Disease and Amyloid: Culprit or Coincidence?
    • I Introduction
    • II Amyloid and AD
    • III Tau and AD
    • IV AD and Tau: A Double Act?
    • V White Matter Pathology and AD
    • VI Transgenic Animal Models for AD: What Have They Taught Us?
    • VII Oxidative Stress and AD
    • VIII Inflammation and AD
    • IX Other Amyloid-Independent Mechanisms in AD
    • X Future Perspectives
  • Chapter 12 Vascular Endothelial Growth Factor and Other Angioglioneurins
    • I Introduction
    • II VEGF
    • III Other Angioglioneurins
    • IV Potential Role of VEGF and Other Angioglioneurins in Brain Restoration
    • V Conclusions
  • Subject Index
  • Contents of Recent Volumes


Central nervous system (CNS) diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis affect a large number of populations worldwide for which no suitable cure is currently available. In addition, stroke, nanoparticle intoxication, diabetes, hypertension, and psychostimulant abuse either alone or in combination are capable of inducing potential brain damage. Thus, there is an urgent need to expand our knowledge to find suitable therapeutic strategies to enhance neurorepair processes in such diseases.

This volume presents neuroprotection and novel therapeutic strategies developed in the last 5 years by 12 world leaders in the field. The term neuroprotection means rescuing neuronal and non-neuronal cells together. The cerebral endothelium that constitutes the anatomical and physiological site of the blood-brain barrier (BBB) is one of the most important non-neural cells in the CNS. Any distortion of the BBB leads to brain diseases and restoration of the barrier results in neuroprotection. Thus, the BBB appears to be the "gateway" for neurological diseases and neurorepair. However, to treat brain tumors or infarcts, new therapeutic strategies are needed to enhance brain drug delivery using nanotechnology. In addition, apart from conventional drugs, restoration of BBB function could also be achieved by means of antibodies directed against specific proteins, neurotransmitters or exogenous supplement of neurotrophic factors. Since co-morbidity factors e.g., hypertension, diabetes, and exposure of nanoparticles could complicate the pathogenesis of neurological disorders either an enhanced dose of the drug or nanodelivery of a combination of several drugs is needed to achieve neuroprotection.

This volume of International Review of Neurobiology is the first to discuss novel therapeutic strategies in situations of neurological disorders in combination with different co-morbidity factors.

Key Features

  • Reviews written by experts in such a way that provides basic knowledge for beginners and advanced information for researchers and experts
  • New aspects of Neurodegenerative diseases such as; Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis are presented with the latest therapeutic measures
  • Exacerbation of brain pathology in hypertension or diabetes is discussed for the first time


Neuroscientists, neurologists, psychologists


No. of pages:
© Academic Press 2012
Academic Press
eBook ISBN:
Hardcover ISBN:


Praise for International Review of Neurobiology:
"Invaluable reading." --NATURE

"A valuable addition to any library as current reference material for advanced undergraduates, graduate students, and professional scientists." --CHOICE

Ratings and Reviews

About the Serial Volume Editors

Hari Shanker Sharma Serial Volume Editor

Dr. Hari Shanker Sharma, Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) is currently working in Uppsala University Hospital, Department of Surgical Sciences, Division of Anesthesiology & Intensive Care Medicine, Uppsala University, Sweden. Dr Sharma obtained his Masters Degree from Bihar University with special expertise in Cell Biology in 1976 and was awarded the Gold Medal of Bihar University for securing 1st position in the 1st Class. Dr Sharma joined the group of Professor Prasanta Kumar Dey, a neurophysiologist, by training in the Department of Physiology, Institute of Medical; Sciences, Banaras Hindu University, Varanasi in 1977 to obtain his Doctor of Philosophy Degree (D.Phil.) in Neurosciences and was awarded his Ph.D. in 1982 on “Blood-Brain Barrier in Stress.” After carrying out a series of Government of India funded Research Projects on the BBB and brain dysfunction (1982–1987), Dr Sharma joined the lab of Neuropathology at Uppsala University with Professor Yngve Olsson in 1988 to investigate passage of tracer transport across the BBB caused by stress or traumatic insults to the Brain and Spinal cord at light and electron microscopy. Dr Sharma was awarded the prestigious Alexander von Humboldt Foundation Fellowship of German Government (1989–1991) to work on hyperthermia induced BBB dysfunction at the ultrastructural level in the laboratory of Professor Jorge Cervós-Navarro (a living “Legend in Neuropathology in Europe”). Dr Sharma again joined Uppsala University and established a network of collaboration on “Experimental CNS Injury Research Group” as a lead investigator with eminent collaborators in various parts of Europe, USA, and Australia (1991–). On his work on hyperthermia Dr Sharma received the prestigious Neuroanatomy award “Rönnows Research prize” of Uppsala University for “best neuroanatomical research of the year 1996” followed by the Award of the Degree of Doctor of Medical Sciences of Uppsala University in Neuroanatomy in 199

Affiliations and Expertise

Professor, Uppsala University, Sweden